JP2003519164A - ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 - Google Patents

ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤

Info

Publication number
JP2003519164A
JP2003519164A JP2001549618A JP2001549618A JP2003519164A JP 2003519164 A JP2003519164 A JP 2003519164A JP 2001549618 A JP2001549618 A JP 2001549618A JP 2001549618 A JP2001549618 A JP 2001549618A JP 2003519164 A JP2003519164 A JP 2003519164A
Authority
JP
Japan
Prior art keywords
peptide
polymer
poly
release
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001549618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003519164A5 (fr
Inventor
ベー． コーン、ヨアヒム
エム． シャクター、デボラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of JP2003519164A publication Critical patent/JP2003519164A/ja
Publication of JP2003519164A5 publication Critical patent/JP2003519164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001549618A 1999-12-31 2001-01-02 ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 Pending JP2003519164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US60/174,137 1999-12-31
PCT/US2001/000030 WO2001049249A2 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Publications (2)

Publication Number Publication Date
JP2003519164A true JP2003519164A (ja) 2003-06-17
JP2003519164A5 JP2003519164A5 (fr) 2011-04-28

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001549618A Pending JP2003519164A (ja) 1999-12-31 2001-01-02 ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤

Country Status (5)

Country Link
EP (1) EP1263453A4 (fr)
JP (1) JP2003519164A (fr)
AU (1) AU784226B2 (fr)
CA (1) CA2396037A1 (fr)
WO (1) WO2001049249A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528866A (ja) * 2009-06-01 2012-11-15 タイレックス・インコーポレイテッド 胸骨創感染症を予防するための組成物および方法
JP2013501106A (ja) * 2009-07-31 2013-01-10 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 天然代謝産物のモノマー類似体から合成された生体吸収性ポリマー

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775905B2 (en) * 1999-12-31 2004-08-19 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1682537T3 (da) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
JP5367692B2 (ja) 2006-02-08 2013-12-11 タイレックス・インコーポレイテッド 一時的補剛メッシュ補綴具
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
CA2667873A1 (fr) 2006-11-06 2008-10-23 Tyrx Pharma, Inc. Pochettes a mailles pour dispositifs medicaux implantables
EP2129339B1 (fr) 2007-03-29 2015-03-04 Tyrx, Inc. Enveloppes polymères biodégradables pour implants mammaires
CA2686214C (fr) 2007-05-02 2016-02-23 Tyrx Pharma, Inc. Polymeres de dihydroxybenzoate et leurs utilisations
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2702984C (fr) 2007-10-19 2017-04-11 Sarcode Corporation Compositions et procedes pour le traitement de la retinopathie diabetique
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
AU2009292949B2 (en) 2008-09-22 2014-10-09 Medtronic, Inc. Linear polyesteramides from aminophenolic esters
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP3489313A1 (fr) 2010-08-25 2019-05-29 Tyrx, Inc. Nouveaux revêtements de dispositifs médicaux
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
US9381281B2 (en) 2011-07-20 2016-07-05 Tyrx, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
IN2015DN00847A (fr) 2012-07-25 2015-06-12 Sarcode Bioscience Inc
EP3718557A3 (fr) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Agoniste du récepteur de la guanylate cyclase sp-333 à utiliser lors du nettoyage du côlon
WO2014137454A1 (fr) 2013-03-07 2014-09-12 Tyrx, Inc. Procédés et compositions permettant d'inhiber l'assemblage de cellules microbiennes se liant de façon irréversible à la surface de dispositifs médicaux
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
AU2014331704A1 (en) 2013-10-10 2016-04-28 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CN105431178A (zh) 2013-11-08 2016-03-23 泰尔克斯公司 用于防止手术切口部位感染的抗微生物组合物及方法
US20170231916A1 (en) * 2014-08-04 2017-08-17 Janssen Sciences Ireland Uc Compacted solid dosage form
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
MXPA99007662A (es) * 1997-02-18 2002-07-22 Univ Rutgers Monomeros derivados de hidroxiacidos, y polimeros preparados a partir de los mismos.
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
WO1999029758A1 (fr) * 1997-12-12 1999-06-17 Samyang Corporation Poly[acide alpha-(omega-aminoalkyl) glycolique] pour le transport d'un agent bioactif par voie tissulaire et penetration cellulaire
EP1073688B1 (fr) * 1998-04-13 2015-03-04 Rutgers, The State University Construction de bibliotheques de copolymeres
WO2000046854A1 (fr) * 1999-02-05 2000-08-10 Alien Technology Corporation Appareils et procedes de formation d'ensembles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528866A (ja) * 2009-06-01 2012-11-15 タイレックス・インコーポレイテッド 胸骨創感染症を予防するための組成物および方法
JP2013501106A (ja) * 2009-07-31 2013-01-10 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 天然代謝産物のモノマー類似体から合成された生体吸収性ポリマー

Also Published As

Publication number Publication date
AU784226B2 (en) 2006-02-23
WO2001049249A2 (fr) 2001-07-12
EP1263453A2 (fr) 2002-12-11
WO2001049249A3 (fr) 2002-01-17
CA2396037A1 (fr) 2001-07-12
EP1263453A4 (fr) 2008-02-20
AU2925501A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
JP2003519164A (ja) ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤
JP4917726B2 (ja) ポリマー混合物および活性化合物からなる徐放用医薬製剤
US7521061B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
CN103827177B (zh) 用于生物活性化合物的受控释放的生物可降解的、半结晶的、相分离的、热塑性多嵌段共聚物
US6589548B1 (en) Controlled drug delivery system using the conjugation of drug to biodegradable polyester
RU2152225C1 (ru) Микрочастицы, включающие соли пептидов с полиэфирами, имеющими концевые карбоксигруппы, и содержащие их композиции
JP6195587B2 (ja) 低バーストポリ−（ラクチド／グリコシド）およびポリマーを生成するための方法
ES2706000T3 (es) Procedimiento de producción de sistemas de administración utilizando composiciones poliméricas biodegradables preformadas
ES2628931T3 (es) Copolímeros multibloque segmentados de fases separadas biodegradables y liberación de polipétidos biológicamente activos
JP2000500803A (ja) トリブロック共重合体を基材とする新規なヒドロゲル、その製造及びその用途
JP2007308500A (ja) Ｇｍ−ｃｓｆの放出の延長
US7781400B2 (en) Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 KDA and processes for their preparation
Stanković et al. Protein release from water-swellable poly (D, L-lactide-PEG)-b-poly (ϵ-caprolactone) implants
Oledzka et al. Polymers in the pharmaceutical applications—natural and bioactive initiators and catalysts in the synthesis of biodegradable and bioresorbable polyesters and polycarbonates
KR100752702B1 (ko) 생분해성 고분자 나노입자 및 그 제조방법
Singh Smart polymer-based controlled-release drug-delivery systems for peptide and protein
Svenson Advances in polymeric matrices and drug particle engineering
US20050271699A1 (en) Biodegradable composition with prolonged release of the biological active compound and preparation thereof
GELATORS I. Polymeric Materials for Drug Delivery

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110303

A524 Written submission of copy of amendment under section 19 (pct)

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110510

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120313

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120803